Patents by Inventor Ziv Sandalon

Ziv Sandalon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
    Patent number: 7563617
    Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: July 21, 2009
    Assignee: The Research Foundation Of State University of New York
    Inventors: Patrick Hearing, Wadie F. Bahou, Ziv Sandalon, Dmitri V. Gnatenko
  • Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
    Publication number: 20060008884
    Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.
    Type: Application
    Filed: May 12, 2005
    Publication date: January 12, 2006
    Applicant: The Research Foundation of State University of New York
    Inventors: Patrick Hearing, Wadie Bahou, Ziv Sandalon, Dmitri Gnatenko
  • Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
    Patent number: 6916635
    Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: July 12, 2005
    Assignee: The Research Foundation of State University of New York
    Inventors: Patrick Hearing, Wadie F. Bahou, Ziv Sandalon, Dmitri V. Gnatenko
  • In vitro construction of SV40 viruses and pseudoviruses
    Patent number: 6830929
    Abstract: The invention relates to constructs capable of infecting mammalian cells comprising at least one semi-purified or pure SV40 capsid protein and a constituent selected from the group consisting of an exogenous DNA, a vector comprising an exogenous DNA, an exogenous RNA, a vector comprising an exogenous RNA, an exogenous protein or peptide product, and antisense RNA, ribozyme RNA or any RNA or DNA which inhibits or prevents the expression of undesired protein(s) in the mammalian cell and optionally further comprising operatively linked regulatory elements sufficient for the expression and/or replication of the exogenous protein in a mammalian cell. The invention further relates to a method for the in vitro construction of SV40 virus or pseudovirus constructs according to the invention.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: December 14, 2004
    Assignees: Yissum Research Development Company of the Hebrew University, Hadasit Medical Research Services and Development Company
    Inventors: Ziv Sandalon, Amos Oppenheim, Ariella Oppenheim
  • Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
    Publication number: 20020102731
    Abstract: The invention provides recombinant vectors including adenovirus/adeno-associated virus (Ad/AAV) vectors and mini-adenovirus (mAd) vectors. Further, the invention provides cells containing these vectors, and methods for making and using the vectors and cells. The compositions and methods of the invention are useful in transferring nucleotide sequences of interest into a cell, including, but not limited to, in gene therapy applications.
    Type: Application
    Filed: February 12, 2001
    Publication date: August 1, 2002
    Applicant: The Research Foundation of State University of New York
    Inventors: Patrick Hearing, Wadie F. Bahou, Ziv Sandalon, Dmitri V. Gnatenko
  • SV-40 derived DNA constructs comprising exogenous DNA sequences
    Patent number: 6090608
    Abstract: The invention relates to DNA constructs comprising an exogenous DNA sequence encoding a therapeutic protein product or itself a therapeutic product, DNA sequences derived from SV40 for replication and packaging of said construct into pseudovirions, and a DNA sequence encoding one or more regulatory elements sufficient for the expression of said therapeutic protein in a mammalian cell operatively linked thereto. The therapeutic product integrated into the DNA constructs of the invention can be a protein selected from the group consisting of enzymes, receptors, structural proteins, regulatory proteins and hormones. Of particular interest are .beta.-globin, P-glycoprotein and apolipoprotein A-I. Specific DNA constructs are plasmids pSO6.beta.-9, pSO6.beta.-1, pSO41, pSM1, and pSAIc. The invention also relates to SV40 pseudovirions containing a DNA construct according to the invention, which are capable of infecting and being expressed in mammalian cells.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: July 18, 2000
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Company Limited
    Inventors: Ariella Oppenheim, Nava Dalyot, Orly Ben-Nun-Shaul, Deborah Rund, Ziv Sandalon, Toba Chajek-Shaul, Shulamit Metzger